As of Q4'25, Pfizer's P/S Ratio reached 8.06, marking a substantial increase from the previous quarter's value of 2.20. This latest data point represents a significant spike compared to the preceding quarters, where the ratio had remained relatively stable. From Q1'23 to Q3'25, the P/S Ratio for Pfizer generally fluctuated within a narrow range between 2.17 and 3.03, indicating a stable valuation relative to sales over this period. However, the sharp jump in Q4'25 stands out as an outlier and suggests a notable change in market sentiment or company fundamentals at the end of the observed timeframe. This area chart highlights a period of stability followed by a dramatic inflection point in the most recent quarter.